Lazertinib
CAS 1903008-80-9Small Molecule
Overview
Lazertinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4558324).
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Lazertinib expires 1 Aug 2041 and exclusivity 19 Aug 2029. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide
- Canonical SMILES
- CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC
- InChIKey
- RRMJMHOQSALEJJ-UHFFFAOYSA-N
Verified Supplier Partner
Do you supply Lazertinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.